Price
$0.162
Decreased by -0.02%
Dollar Volume (20D)
90.93 K
ADR%
12.29
Earnings Report Date (estimate)
Jun 8, 23 (-0.05)
Market Cap.
16.38 M
Shares Float
55.88 M
Shares Outstanding
101.12 M
Beta
1.31
Price / Earnings
-0.58
BPR
4.73
20D Range
0.15 0.23
50D Range
0.14 0.27
200D Range
0.14 1.39
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Mar 31, 20 -0.39
Decreased by -160.00%
-0.14
Decreased by -1.28 K%
Nov 4, 19 -0.14
Increased by +73.58%
-0.12
Decreased by -138.89%
Aug 29, 19 -0.25
Increased by +52.83%
-0.13
Decreased by -710.06%
May 29, 19 -0.15
Decreased by -66.67%
-0.05
Decreased by -4.00 K%
Apr 23, 19 -0.15
Increased by +85.00%
-0.05
Decreased by -4.00 K%
Sep 27, 18 -0.53
Increased by +47.00%
-0.44
Decreased by -46.49%
Aug 17, 18 -0.53
Decreased by -5.92 K%
-0.44
Decreased by -46.49%
Aug 16, 18 -0.09
Decreased by -50.00%
-0.47
Increased by +172.02%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Jun 30, 22 0.00
Decreased by N/A%
-5.54 M
Decreased by -26.70%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by N/A%
-5.11 M
Increased by +12.50%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 0.00
Decreased by N/A%
-5.61 M
Increased by +17.72%
Decreased by N/A%
Decreased by N/A%
Sep 30, 21 0.00
Decreased by N/A%
-1.43 M
Decreased by -198.83%
Decreased by N/A%
Decreased by N/A%
Jun 30, 21 0.00
Decreased by N/A%
-4.38 M
Increased by +47.39%
Decreased by N/A%
Decreased by N/A%
Mar 31, 21 0.00
Decreased by N/A%
-5.84 M
Decreased by -72.48%
Decreased by N/A%
Decreased by N/A%
Dec 31, 20 0.00
Decreased by N/A%
-6.82 M
Increased by +13.41%
Decreased by N/A%
Decreased by N/A%
Sep 30, 20 0.00
Decreased by N/A%
1.44 M
Increased by +156.21%
Increased by +N/A%
Decreased by N/A%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.